Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.

Clinical pharmacology and therapeutics - 1 Jul 2004

Sparreboom Alex, Gelderblom Hans, Marsh Sharon, Ahluwalia Ranjeet, Obach Rosendo, Principe Paola, Twelves Chris, Verweij Jaap, McLeod Howard L

Abstract excerpt

OBJECTIVE: The adenosine triphosphate-binding cassette transporter ABCG2 (breast cancer resistance protein [BCRP]) functions as an efflux transporter for many drugs, including the topoisomerase I inhibitor diflomotecan, and is expressed at high levels in the intestine and liver. We performed an exploratory analysis to evaluate the effects of the natural allelic variant ABCG2 421C>A on the pharmacokinetics of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to ATP-Binding Cassette Transporters

Share to Camptothecin

Share to Multidrug Resistance-Associated Protein 2

Share to Neoplasm Proteins

Source

Identifiers

PMID: 15229462
DOI: 10.1016/j.clpt.2004.03.003

Genes

ABCG2
ABCB1
ABCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.PMID 15229462Read ↗

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.Semantic proximity Read ↗

BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.Semantic proximity Read ↗

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.Semantic proximity Read ↗

Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.Semantic proximity Read ↗

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.Semantic proximity Read ↗

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.Semantic proximity Read ↗

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Effect of ABCG2 genotype on the oral bioavailability of topotecan.Semantic proximity Read ↗

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.Semantic proximity Read ↗

Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study.Semantic proximity Read ↗

Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort studySemantic proximity Read ↗

Irinotecan pathway genotype analysis to predict pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.